Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $8.39 Consensus PT from Analysts

Revance Therapeutics, Inc. (NASDAQ:RVNC) has received an average rating of “Hold” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $8.39.

Several research firms recently issued reports on RVNC. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Mizuho dropped their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. StockNews.com assumed coverage on shares of Revance Therapeutics in a report on Tuesday, March 18th. They set a “hold” rating on the stock. Finally, Barclays dropped their target price on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd.

Revance Therapeutics Price Performance

RVNC opened at $3.65 on Monday. The stock has a market capitalization of $381.02 million, a PE ratio of -1.89 and a beta of 0.90. The firm’s fifty day moving average price is $3.62 and its 200 day moving average price is $4.23. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $6.65.

Hedge Funds Weigh In On Revance Therapeutics

Several institutional investors have recently modified their holdings of RVNC. LMR Partners LLP bought a new position in Revance Therapeutics in the 3rd quarter valued at about $11,648,000. Alpine Associates Management Inc. bought a new position in Revance Therapeutics in the 3rd quarter valued at about $21,605,000. Oddo BHF Asset Management Sas bought a new position in Revance Therapeutics in the 3rd quarter valued at about $3,763,000. FNY Investment Advisers LLC grew its position in Revance Therapeutics by 160.4% in the 4th quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock valued at $1,452,000 after buying an additional 294,323 shares in the last quarter. Finally, Wellington Management Group LLP bought a new position in Revance Therapeutics in the 3rd quarter valued at about $2,315,000. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.